The Role of the Advanced Practitioner in Enhancing Outcomes
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2019;10(suppl 4):19–22 |
© 2019 Harborside™
Advanced practitioners (nurse practitioners, physician assistants, pharmacists, and other health-care providers) have become increasingly integral members of the oncology care team. The accelerated rate of approvals for new therapies in acute myeloid leukemia highlights the imperative of timely collaboration between the entire team.
This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Table of Contents
- Acute Myeloid Leukemia: An Ever-Changing Disease
- Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
- The Role of the Advanced Practitioner in Enhancing Outcomes (current article)
- Appendix: Key Information on Newly Approved AML Drugs
For access to the full length article, please sign in